{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:05:57Z","timestamp":1793361957580,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Perioper Med"],"DOI":"10.1186\/s13741-025-00548-2","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:49:27Z","timestamp":1751636967000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A case of perioperative euglycemic ketoacidosis in a patient without diabetes: are current guidelines enough?"],"prefix":"10.1186","volume":"14","author":[{"given":"Shushmita","family":"Hoque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Teague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"issue":"Supplement_1","key":"548_CR1","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 9 Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025. Diabetes Care. 2024;48(Supplement_1):S181\u2013206.","journal-title":"Diabetes Care."},{"issue":"16","key":"548_CR2","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"key":"548_CR3","doi-asserted-by":"crossref","unstructured":"Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, et al. Effects of dapagliflozin in stage 4 chronic kidney disease. J Am Soc Nephrol. 2021;32(9). Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34272327\/&nbsp. Cited 2025 Mar 9.","DOI":"10.1681\/ASN.2021020167"},{"issue":"5","key":"548_CR4","doi-asserted-by":"publisher","first-page":"e003666","DOI":"10.1136\/bmjdrc-2023-003666","volume":"11","author":"E Chow","year":"2023","unstructured":"Chow E, Clement S, Garg R. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2023;11(5):e003666.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"10S","key":"548_CR5","doi-asserted-by":"publisher","first-page":"S516","DOI":"10.14309\/01.ajg.0000952452.83727.2e","volume":"118","author":"JT Chumbe","year":"2023","unstructured":"Chumbe JT, Annie F, Ayoub M, Aijaz P, Rajamanuri M, Naravadi V. S703 Risk of diabetic ketoacidosis post-colonoscopy in patients with type 2 DM taking sodium-glucose co-transporter-2 inhibitors. Off J Am Coll Gastroenterol ACG. 2023;118(10S):S516.","journal-title":"Off J Am Coll Gastroenterol ACG"},{"key":"548_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2024.7082","author":"AA Dixit","year":"2025","unstructured":"Dixit AA, Bateman BT, Hawn MT, Odden MC. Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis. JAMA Surg. 2025. Available from: https:\/\/doi.org\/10.1001\/jamasurg.2024.7082&nbsp. Cited 2025 Mar 9.","journal-title":"JAMA Surg"},{"key":"548_CR7","doi-asserted-by":"crossref","unstructured":"Fioretto P, Avogaro A. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opin Pharmacother. 2017;18(5):517\u201327.","DOI":"10.1080\/14656566.2017.1300253"},{"issue":"2","key":"548_CR8","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11606-024-09073-2","volume":"40","author":"R Garg","year":"2025","unstructured":"Garg R, Sood N, Bansal O, Hoskote A. Euglycemic ketoacidosis associated with SGLT-2 inhibitors in non-diabetic patients\u2014a narrative review. J Gen Intern Med. 2025;40(2):437\u201342.","journal-title":"J Gen Intern Med"},{"issue":"6","key":"548_CR9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4158\/EP161292.PS","volume":"22","author":"Y Handelsman","year":"2016","unstructured":"Handelsman Y, Henry RR, Bloomgarden ZT, Dagogo-Jack S, DeFronzo RA, Einhorn D, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of SGLT-2 Inhibitors and Diabetic Ketoacidosis. Endocr Pract. 2016;22(6):753\u201362 Elsevier.","journal-title":"Endocr Pract."},{"issue":"18","key":"548_CR10","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation American Heart Association. 2022;145(18):e895-1032.","journal-title":"Circulation. American Heart Association."},{"issue":"21","key":"548_CR11","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","volume":"149","author":"AF Hernandez","year":"2024","unstructured":"Hernandez AF, Udell JA, Jones WS, Anker SD, Petrie MC, Harrington J, et al. Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial. Circulation. 2024;149(21):1627\u201338.","journal-title":"Circulation"},{"key":"548_CR12","unstructured":"Hwang SM, Abcejo AS, Jacob AK, Raiten JM, Mundi MS. Editorial: Euglycemic ketoacidosis concerns in perioperative use of SGLT2 inhibitors: re-examining current recommendations. Anesth Patient Saf Found. 2025. Available from: https:\/\/www.apsf.org\/article\/editorial-euglycemic-ketoacidosis-concerns-in-perioperative-use-of-sglt2-inhibitors-re-examining-current-recommendations\/&nbsp. Cited 2025 Mar 9."},{"issue":"Suppl_1","key":"548_CR13","first-page":"A4145352","volume":"150","author":"S Khadka","year":"2024","unstructured":"Khadka S, Rajak K, Matai P, Timilsina B, Sharma S, Halder A, et al. Abstract 4145352: SGLT2 inhibitor-induced euglycemic ketoacidosis in a non-diabetic patient with ischemic cardiomyopathy. Circulation American Heart Association. 2024;150(Suppl_1):A4145352\u2013A4145352.","journal-title":"Circulation. American Heart Association."},{"key":"548_CR14","unstructured":"Kumar S, Bhavnani S, Goyal P, Rich M, Krishnaswami A. Preoperative cessation of SGLT2i. Am Coll Cardiol. Available from: https:\/\/www.acc.org\/Latest-in-Cardiology\/Articles\/2022\/10\/07\/17\/21\/http%3a%2f%2fwww.acc.org%2fLatest-in-Cardiology%2fArticles%2f2022%2f10%2f07%2f17%2f21%2fPreoperative-Cessation-of-SGLT2i&nbsp. Cited 2025 Mar 9."},{"issue":"5","key":"548_CR15","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.bja.2025.01.037","volume":"134","author":"XQ Li","year":"2025","unstructured":"Li XQ, Mirsaidi N, Bauman J, Marino J, Harris YT, Schulman-Rosenbaum R. Updates on perioperative cessation of SGLT2 inhibitors. Br J Anaesth. 2025;134(5):1523\u20135.","journal-title":"Br J Anaesth"},{"issue":"8","key":"548_CR16","doi-asserted-by":"publisher","first-page":"100851","DOI":"10.1016\/j.xkme.2024.100851","volume":"6","author":"M Madero","year":"2024","unstructured":"Madero M, Chertow GM, Mark PB. SGLT2 inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health. Kidney Med. 2024;6(8):100851.","journal-title":"Kidney Med"},{"issue":"9","key":"548_CR17","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.eprac.2022.06.006","volume":"28","author":"PB Mehta","year":"2022","unstructured":"Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient perioperative euglycemic diabetic ketoacidosis due to sodium-glucose cotransporter-2 inhibitors\u2013lessons from a case series and strategies to decrease incidence. Endocr Pract. 2022;28(9):884\u20138 Elsevier.","journal-title":"Endocr Pract."},{"issue":"11","key":"548_CR18","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.2337\/dc20-1244","volume":"43","author":"EJ Meyer","year":"2020","unstructured":"Meyer EJ, Mignone E, Hade A, Thiruvenkatarajan V, Bryant RV, Jesudason D. Periprocedural euglycemic diabetic ketoacidosis associated with sodium\u2013glucose cotransporter 2 inhibitor therapy during colonoscopy. Diabetes Care. 2020;43(11):e181\u20134.","journal-title":"Diabetes Care"},{"key":"548_CR19","doi-asserted-by":"crossref","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.\u00a0N Engl J Med. 2017;377(7):644\u201357.","DOI":"10.1056\/NEJMoa1611925"},{"issue":"2","key":"548_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.bja.2024.05.004","volume":"133","author":"MJP Oosterom-Eijmael","year":"2024","unstructured":"Oosterom-Eijmael MJP, Hermanides J, van Raalte DH, Hulst AH. Risk of perioperative discontinuation of SGLT2 inhibitors. Br J Anaesth Elsevier. 2024;133(2):239\u201340.","journal-title":"Br. J. Anaesth. Elsevier."},{"key":"548_CR21","doi-asserted-by":"crossref","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015;38(9):1687\u201393.","DOI":"10.2337\/dc15-0843"},{"issue":"1","key":"548_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.jvca.2023.10.011","volume":"38","author":"JM Raiten","year":"2024","unstructured":"Raiten JM, Morlok A, D\u2019Ambrosia S, Ruggero MA, Flood J. Perioperative management of patients receiving sodium-glucose cotransporter 2 inhibitors: development of a clinical guideline at a large academic medical center. J Cardiothorac Vasc Anesth. 2024;38(1):57\u201366.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"548_CR23","doi-asserted-by":"crossref","unstructured":"Rosenstock J, Ferrannini E. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care. 2015;38(9):1638\u201342.","DOI":"10.2337\/dc15-1380"},{"issue":"3","key":"548_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00540-023-03174-8","volume":"37","author":"H Seki","year":"2023","unstructured":"Seki H, Ideno S, Shiga T, Watanabe H, Ono M, Motoyasu A, et al. Sodium-glucose cotransporter 2 inhibitor-associated perioperative ketoacidosis: a systematic review of case reports. J Anesth. 2023;37(3):465\u201373.","journal-title":"J Anesth"},{"issue":"4","key":"548_CR25","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4):S117-314 Elsevier.","journal-title":"Kidney Int."},{"issue":"1","key":"548_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bja.2019.03.028","volume":"123","author":"V Thiruvenkatarajan","year":"2019","unstructured":"Thiruvenkatarajan V, Meyer EJ, Nanjappa N, Wijk RMV, Jesudason D. Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review. Br J Anaesth. 2019;123(1):27\u201336 Elsevier.","journal-title":"Br. J. Anaesth."},{"issue":"1","key":"548_CR27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2337\/dc23-1163","volume":"47","author":"MM Umapathysivam","year":"2023","unstructured":"Umapathysivam MM, Gunton J, Stranks SN, Jesudason D. Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium\u2013glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction. Diabetes Care. 2023;47(1):140\u20133.","journal-title":"Diabetes Care"},{"issue":"8","key":"548_CR28","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2337\/dci24-0032","volume":"47","author":"GE Umpierrez","year":"2024","unstructured":"Umpierrez GE, Davis GM, ElSayed NA, Fadini GP, Galindo RJ, Hirsch IB, et al. Hyperglycemic crises in adults with diabetes: a consensus report. Diabetes Care. 2024;47(8):1257\u201375.","journal-title":"Diabetes Care"},{"key":"548_CR29","unstructured":"U.S. Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. FDA. 2023. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious&nbsp. Cited 2025 Mar 9."},{"issue":"2","key":"548_CR30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2337\/ds23-0040","volume":"37","author":"M Verdone","year":"2024","unstructured":"Verdone M, Bauman J, Iversen E, Schulman-Rosenbaum R, Antonacci A, Leffe S, et al. Novel approach to continuation of elective procedures in people at risk for sodium\u2013glucose cotransporter 2 inhibitor\u2013associated euglycemic ketoacidosis. Diabetes Spectr Publ Am Diabetes Assoc. 2024;37(2):165\u20139.","journal-title":"Diabetes Spectr Publ Am Diabetes Assoc"},{"issue":"3","key":"548_CR31","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374.","journal-title":"Nat Med"},{"key":"548_CR32","doi-asserted-by":"crossref","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.\u00a0N Engl J Med. 2015;373(22):2117\u201328.","DOI":"10.1056\/NEJMoa1504720"}],"container-title":["Perioperative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13741-025-00548-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13741-025-00548-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13741-025-00548-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T13:49:30Z","timestamp":1751636970000},"score":1,"resource":{"primary":{"URL":"https:\/\/perioperativemedicinejournal.biomedcentral.com\/articles\/10.1186\/s13741-025-00548-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["548"],"URL":"https:\/\/doi.org\/10.1186\/s13741-025-00548-2","relation":{},"ISSN":["2047-0525"],"issn-type":[{"value":"2047-0525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of their clinical details and\/or clinical\u00a0images was obtained from the patient\/parent\/guardian\/ relative of the patient. A copy of the consent form is available for review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}